治疗糖尿病肾病的新型醛固酮受体拮抗剂——非奈利酮

Finerenone:A Novel Aldosterone Receptor Antagonist for the Treatment of Diabetic Nephropathy

糖尿病肾病发病率高,危害重大,临床表现主要为持续性的白蛋白尿或肾小球滤过率进行性下降。非奈利酮是继螺内酯和依普利酮之后的第3代醛固酮受体拮抗剂。2021年7月9日,美国食品药品管理局批准非奈利酮上市申请,用于治疗患有2型糖尿病的慢性肾病。2021年2月,非奈利酮在中国的上市申请获得国家药品监督管理局药品审评中心受理。临床试验显示非奈利酮为2型糖尿病肾病患者带来心、肾双重获益,且安全性良好,有望与肾素-血管紧张素系统阻断剂和钠-葡萄糖协同转运蛋白2抑制剂一同成为管理糖尿病肾病的“三驾马车”。

Diabetic nephropathy has a high incidence rate and severe harm.The clinical manifestations are characterized by persistent albuminuria or progressively decreased glomerular filtration rate(GFR).Finerenone is the third-generation of aldosterone receptor antagonist after spironolactone and eplerenone.On July 9,2021,the U.S.Food and Drug Administration approved the marketing application for finerenone to treat chronic kidney disease with type 2 diabetes.In February 2021,it was accepted by the Drug Evaluation Center of State Drug Administration of China.Clinical trials have shown that finerenone can bring both cardiac and renal benefits to patients with type 2 diabetic nephropathy with reasonable safety.It is expected to become one of the"troika"for the management of diabetic nephropathy along with renin-angiotensin system blockers and sodium-glucose co-transporter 2 inhibitors.